Weekly Recap | Roivant Sciences +0.28%, most brokers rate it buyWeekly Review·2 days ago, 12:38 AMROIV+0.65%
Mayukh Sukhatme Sells 17,519 Shares of Roivant Sciences (NASDAQ:ROIV) StockMarket Beat·2 days ago, 10:07 PMROIV+0.65%
Roivant President, CIO Mayukh Sukhatme disposes of common shares worth $12.47 millionPUBT·2 days ago, 08:01 PMROIV+0.65%
Roivant President, CIO Mayukh Sukhatme disposes of USD 24.12 million in common sharesPUBT·Aug 18 at 08:00 PMROIV+0.65%
How Investors May Respond To Roivant Sciences (ROIV) Narrowing Losses Despite Weaker Quarterly RevenueSimplywall·Aug 16 at 10:49 AMROIV+0.65%
9 Health Care Stocks Whale Activity In Today’s Sessionbenzinga_article·Aug 14 at 12:35 PMROIV+0.65%AMGN+0.95%
Guggenheim Issues Positive Forecast for Roivant Sciences (NASDAQ:ROIV) Stock PriceMarket Beat·Aug 7 at 12:24 PMROIV+0.65%
Piper Sandler Reaffirms Their Buy Rating on Roivant Sciences (ROIV)Tip Ranks·Aug 7 at 10:28 AMROIV+0.65%
Roivant Sciences Ltd. Stock 12‑Month Price Target Raised to $39.73, Implies 15% UpsideTradingView·Aug 6 at 06:20 PMROIV+0.65%
Roivant Sciences | 8-K: FY2027 Q1 Revenue Misses Estimate at USD 1.442 MEarnings Watch·Aug 6 at 06:17 AMROIV+0.65%
Roivant unit Priovant begins Phase 3 BEACON+ trial of brepocitinib in cutaneous sarcoidosisPUBT·Aug 6 at 06:07 AMROIV+0.65%
Roivant Q1 FY27 net loss widens to $290.61 million; revenue slips to $1.44 millionPUBT·Aug 6 at 06:07 AMROIV+0.65%
